Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed

PRCT among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+37.2%22nd of 155 · median +10.5%
Net margin
-4.1%15.3%
-32.6%132nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
-34.9%125th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-24.1%127th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.1613th of 108 · median 0.69

PRCT and 9 peers, year by year

The 9 Health care companies closest to PRCT in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
PRCT PROCEPT BioRobotics Corp FY2025 $308.1M+37.2%63.7%−33.7%−31.0%−18.9%−26.1%0.14
VCEL Vericel Corp FY2025 $276.3M+16.5%74.4%4.0%6.0%9.0%4.7%-
RYTM Rhythm Pharmaceuticals, Inc. FY2025 $189.8M+45.8%-−101.2%−103.6%−61.5%−141.3%0.78
TWST Twist Bioscience Corp FY2025 $376.6M+20.3%-−36.2%−20.6%−20.1%−16.4%-
LMAT Lemaitre Vascular Inc FY2025 $249.6M+13.5%71.5%27.2%23.1%29.8%14.7%-
ZLAB Zai Lab Ltd FY2025 $460.2M+15.0%-−49.9%−38.1%−34.5%−24.5%0.29
LGND Ligand Pharmaceuticals Inc FY2025 $268.1M+60.4%-15.3%46.4%18.2%12.2%-
WGS GeneDx Holdings Corp. FY2025 $427.5M+40.0%69.7%−3.1%−4.9%3.3%−6.8%0.18
KRYS Krystal Biotech, Inc. FY2025 $389.1M+33.9%-41.5%52.6%48.5%16.8%-
RVMD Revolution Medicines, Inc. FY2025 $0-----−69.3%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2020 to FY2025 · 10-K XBRL

PRCTPROCEPT BioRobotics Corp
FY2020 revenue $7.7MFY2021 revenue $34.5MFY2022 revenue $75.0MFY2023 revenue $136.2MFY2024 revenue $224.5MFY2025 revenue $308.1M FY2020 net margin −687.0%FY2021 net margin −173.6%FY2022 net margin −116.2%FY2023 net margin −77.8%FY2024 net margin −40.7%FY2025 net margin −31.0% FY2020FY2025
Revenue$308.1M Growth+37.2% Net margin−31.0%
VCELVericel Corp
FY2020 revenue $124.2MFY2021 revenue $156.2MFY2022 revenue $164.4MFY2023 revenue $197.5MFY2024 revenue $237.2MFY2025 revenue $276.3M FY2020 net margin 2.3%FY2021 net margin −4.8%FY2022 net margin −10.2%FY2023 net margin −1.6%FY2024 net margin 4.4%FY2025 net margin 6.0% FY2020FY2025
Revenue$276.3M Growth+16.5% Net margin6.0%
RYTMRhythm Pharmaceuticals, Inc.
FY2021 revenue $3.2MFY2022 revenue $23.6MFY2023 revenue $77.4MFY2024 revenue $130.1MFY2025 revenue $189.8M FY2022 net margin −766.2%FY2023 net margin −238.5%FY2024 net margin −200.3%FY2025 net margin −103.6% FY2020FY2025
Revenue$189.8M Growth+45.8% Net margin−103.6%
TWSTTwist Bioscience Corp
FY2020 revenue $90.1MFY2021 revenue $132.3MFY2022 revenue $203.6MFY2023 revenue $245.1MFY2024 revenue $313.0MFY2025 revenue $376.6M FY2020 net margin −155.3%FY2021 net margin −114.9%FY2022 net margin −107.0%FY2023 net margin −83.5%FY2024 net margin −66.7%FY2025 net margin −20.6% FY2020FY2025
Revenue$376.6M Growth+20.3% Net margin−20.6%
LMATLemaitre Vascular Inc
FY2020 revenue $129.4MFY2021 revenue $154.4MFY2022 revenue $161.7MFY2023 revenue $193.5MFY2024 revenue $219.9MFY2025 revenue $249.6M FY2020 net margin 16.4%FY2021 net margin 17.4%FY2022 net margin 12.8%FY2023 net margin 15.6%FY2024 net margin 20.0%FY2025 net margin 23.1% FY2020FY2025
Revenue$249.6M Growth+13.5% Net margin23.1%
ZLABZai Lab Ltd
FY2020 revenue $49.0MFY2021 revenue $144.3MFY2022 revenue $215.0MFY2023 revenue $266.7MFY2024 revenue $399.0MFY2025 revenue $460.2M FY2020 net margin −549.3%FY2021 net margin −488.2%FY2022 net margin −206.1%FY2023 net margin −125.5%FY2024 net margin −64.4%FY2025 net margin −38.1% FY2020FY2025
Revenue$460.2M Growth+15.0% Net margin−38.1%
LGNDLigand Pharmaceuticals Inc
FY2020 revenue $163.6MFY2021 revenue $241.5MFY2022 revenue $196.2MFY2023 revenue $131.3MFY2024 revenue $167.1MFY2025 revenue $268.1M FY2020 net margin −1.8%FY2021 net margin 23.7%FY2022 net margin −17.0%FY2023 net margin 39.7%FY2024 net margin −2.4%FY2025 net margin 46.4% FY2020FY2025
Revenue$268.1M Growth+60.4% Net margin46.4%
WGSGeneDx Holdings Corp.
FY2020 revenue $179.3MFY2021 revenue $212.2MFY2022 revenue $234.7MFY2023 revenue $202.6MFY2024 revenue $305.4MFY2025 revenue $427.5M FY2020 net margin −134.6%FY2021 net margin −115.6%FY2022 net margin −233.9%FY2023 net margin −86.8%FY2024 net margin −17.1%FY2025 net margin −4.9% FY2020FY2025
Revenue$427.5M Growth+40.0% Net margin−4.9%
KRYSKrystal Biotech, Inc.
FY2023 revenue $50.7MFY2024 revenue $290.5MFY2025 revenue $389.1M FY2023 net margin 21.6%FY2024 net margin 30.7%FY2025 net margin 52.6% FY2020FY2025
Revenue$389.1M Growth+33.9% Net margin52.6%
RVMDRevolution Medicines, Inc.
FY2020 revenue $43.0MFY2021 revenue $29.4MFY2022 revenue $35.4MFY2023 revenue $11.6M FY2020 net margin −251.6%FY2021 net margin −636.6%FY2022 net margin −703.0% FY2020FY2025
Revenue$0 Growth−100% Net margin−703.0%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2020 to FY2025

Revenue as reported in the 10-K.

$0 $460.2M FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: $124.2M, $156.2M, $164.4M, $197.5M, $237.2M, $276.3M VCEL RYTM: $0, $3.2M, $23.6M, $77.4M, $130.1M, $189.8M RYTM TWST: $90.1M, $132.3M, $203.6M, $245.1M, $313.0M, $376.6M TWST LMAT: $129.4M, $154.4M, $161.7M, $193.5M, $219.9M, $249.6M LMAT ZLAB: $49.0M, $144.3M, $215.0M, $266.7M, $399.0M, $460.2M ZLAB LGND: $163.6M, $241.5M, $196.2M, $131.3M, $167.1M, $268.1M LGND WGS: $179.3M, $212.2M, $234.7M, $202.6M, $305.4M, $427.5M WGS KRYS: -, $0, $0, $50.7M, $290.5M, $389.1M KRYS RVMD: $43.0M, $29.4M, $35.4M, $11.6M, $0, $0 RVMD PRCT: $7.7M, $34.5M, $75.0M, $136.2M, $224.5M, $308.1M PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $460.2M. A gap is a year with no number. A ring marks where a line starts: KRYS has no earlier 10-K here. LGND: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2020 to FY2025

Revenue against the fiscal year before.

−100% +649% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: +3.5%, +25.5%, +6.9%, +20.7%, +20.1%, +16.5% VCEL RYTM: -, -, +649%, +228%, +68.1%, +45.8% RYTM TWST: +65.7%, +46.9%, +53.8%, +20.4%, +27.7%, +20.3% TWST LMAT: +10.4%, +19.4%, +4.7%, +19.7%, +13.6%, +13.5% LMAT ZLAB: +277%, +194%, +47.6%, +25.4%, +49.1%, +15.0% ZLAB LGND: +55.0%, +47.7%, −18.8%, −33.1%, +27.3%, +60.4% LGND WGS: −8.6%, +18.3%, +10.6%, −13.7%, +50.8%, +40.0% WGS KRYS: -, -, -, -, +473%, +33.9% KRYS RVMD: −14.1%, −31.6%, +20.4%, −67.3%, −100%, - RVMD PRCT: -, +347%, +118%, +81.6%, +64.8%, +37.2% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −100% to +649%. A gap is a year with no number. A ring marks where a line starts: PRCT, RYTM, KRYS have no earlier 10-K here.

Gross margin, FY2020 to FY2025

Gross profit / revenue.

−16.3% 74.4% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: 67.8%, 67.9%, 66.8%, 68.6%, 72.6%, 74.4% VCEL LMAT: 65.4%, 65.7%, 64.9%, 65.7%, 68.6%, 71.5% LMAT WGS: 2.2%, −7.8%, −11.4%, 44.4%, 63.6%, 69.7% WGS PRCT: −16.3%, 46.0%, 49.4%, 52.2%, 61.1%, 63.7% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −16.3% to 74.4%. A gap is a year with no number.
CompanyFY2020FY2021FY2022FY2023FY2024FY2025
PRCT Dec −16.3%46.0%49.4%52.2%61.1%63.7%
VCEL Dec 67.8%67.9%66.8%68.6%72.6%74.4%
RYTM Dec ------
TWST Sep ------
LMAT Dec 65.4%65.7%64.9%65.7%68.6%71.5%
ZLAB Dec ------
LGND Dec ------
WGS Dec 2.2%−7.8%−11.4%44.4%63.6%69.7%
KRYS Dec ------
RVMD Dec ------
Peer median65.4%65.7%64.9%65.7%68.6%71.5%

Operating margin, FY2020 to FY2025

Operating income / revenue.

−757.9% 43.0% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: 1.9%, −5.0%, −10.4%, −3.3%, 1.9%, 4.0% VCEL RYTM: -, n/m, −757.9%, −238.1%, −204.0%, −101.2% RYTM TWST: −155.5%, −115.4%, −115.3%, −88.6%, −70.6%, −36.2% TWST LMAT: 22.3%, 23.6%, 16.6%, 19.0%, 23.8%, 27.2% LMAT ZLAB: −616.4%, −485.1%, −188.0%, −137.4%, −70.7%, −49.9% ZLAB LGND: 22.9%, 43.0%, 1.5%, 9.1%, −13.5%, 15.3% LGND WGS: −134.9%, −210.3%, −284.5%, −89.2%, −7.6%, −3.1% WGS KRYS: -, -, -, −216.2%, 22.6%, 41.5% KRYS RVMD: −257.5%, −639.7%, −730.0%, n/m, -, - RVMD PRCT: −619.4%, −157.1%, −107.6%, −80.2%, −43.0%, −33.7% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −757.9% to 43.0%. A gap is a year with no number. A ring marks where a line starts: RYTM, KRYS have no earlier 10-K here.

Net margin, FY2020 to FY2025

Net income / revenue.

−766.2% 52.6% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: 2.3%, −4.8%, −10.2%, −1.6%, 4.4%, 6.0% VCEL RYTM: -, n/m, −766.2%, −238.5%, −200.3%, −103.6% RYTM TWST: −155.3%, −114.9%, −107.0%, −83.5%, −66.7%, −20.6% TWST LMAT: 16.4%, 17.4%, 12.8%, 15.6%, 20.0%, 23.1% LMAT ZLAB: −549.3%, −488.2%, −206.1%, −125.5%, −64.4%, −38.1% ZLAB LGND: −1.8%, 23.7%, −17.0%, 39.7%, −2.4%, 46.4% LGND WGS: −134.6%, −115.6%, −233.9%, −86.8%, −17.1%, −4.9% WGS KRYS: -, -, -, 21.6%, 30.7%, 52.6% KRYS RVMD: −251.6%, −636.6%, −703.0%, n/m, -, - RVMD PRCT: −687.0%, −173.6%, −116.2%, −77.8%, −40.7%, −31.0% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −766.2% to 52.6%. A gap is a year with no number. A ring marks where a line starts: RYTM, KRYS have no earlier 10-K here.

Free cash flow, FY2020 to FY2025

Cash from operations minus capital spending.

−$913.7M $188.9M FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: $14.9M, $21.1M, $10.1M, $15.3M, −$5.8M, $24.7M VCEL RYTM: −$122.2M, −$146.4M, −$173.7M, −$136.2M, −$113.9M, −$116.6M RYTM TWST: −$152.1M, −$139.3M, −$226.2M, −$170.3M, −$69.2M, −$75.6M TWST LMAT: $31.8M, $30.2M, $22.1M, $29.5M, $37.2M, $74.5M LMAT ZLAB: −$226.2M, −$567.5M, −$392.2M, −$205.4M, −$220.5M, −$158.9M ZLAB LGND: $50.1M, $70.0M, $119.9M, $46.1M, $95.2M, $48.9M LGND WGS: −$117.2M, −$199.8M, −$326.3M, −$185.4M, −$34.0M, $14.3M WGS KRYS: −$40.9M, −$116.3M, −$153.5M, −$100.6M, $119.2M, $188.9M KRYS RVMD: −$103.0M, −$153.7M, −$235.2M, −$358.3M, −$567.7M, −$913.7M RVMD PRCT: −$48.6M, −$57.9M, −$83.0M, −$133.2M, −$103.6M, −$58.3M PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$913.7M to $188.9M. A gap is a year with no number.

FCF margin, FY2020 to FY2025

Free cash flow / revenue.

−734.9% 61.1% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: 12.0%, 13.5%, 6.1%, 7.7%, −2.4%, 9.0% VCEL RYTM: -, n/m, −734.9%, −175.9%, −87.5%, −61.5% RYTM TWST: −168.8%, −105.3%, −111.1%, −69.5%, −22.1%, −20.1% TWST LMAT: 24.6%, 19.6%, 13.7%, 15.2%, 16.9%, 29.8% LMAT ZLAB: −462.0%, −393.3%, −182.4%, −77.0%, −55.3%, −34.5% ZLAB LGND: 30.6%, 29.0%, 61.1%, 35.1%, 57.0%, 18.2% LGND WGS: −65.4%, −94.2%, −139.0%, −91.5%, −11.1%, 3.3% WGS KRYS: -, -, -, −198.4%, 41.0%, 48.5% KRYS RVMD: −239.6%, −523.0%, −664.8%, n/m, -, - RVMD PRCT: −629.5%, −168.0%, −110.7%, −97.8%, −46.2%, −18.9% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −734.9% to 61.1%. A gap is a year with no number. A ring marks where a line starts: RYTM, KRYS have no earlier 10-K here.

Return on equity, FY2020 to FY2025

Net income / shareholders' equity at the year end.

−141.3% 16.8% FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: 2.1%, −4.4%, −8.7%, −1.4%, 3.5%, 4.7% VCEL RYTM: −80.5%, −24.5%, −68.5%, −108.8%, n/m, −141.3% RYTM TWST: −41.6%, −26.2%, −27.6%, −32.8%, −44.2%, −16.4% TWST LMAT: 12.3%, 10.6%, 7.7%, 10.1%, 13.1%, 14.7% LMAT ZLAB: −23.0%, −51.1%, −42.4%, −42.0%, −30.6%, −24.5% ZLAB LGND: −0.4%, 7.0%, −5.6%, 7.4%, −0.5%, 12.2% LGND WGS: n/m, −63.2%, n/m, −77.1%, −21.3%, −6.8% WGS KRYS: −11.0%, −11.7%, −26.8%, 1.4%, 9.4%, 16.8% KRYS RVMD: −22.8%, −31.0%, −36.3%, −23.9%, −26.5%, −69.3% RVMD PRCT: n/m, −22.4%, −44.2%, −37.7%, −22.7%, −26.1% PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −141.3% to 16.8%. A gap is a year with no number. A ring marks where a line starts: PRCT, WGS have no earlier 10-K here.

Debt / equity, FY2020 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.05 FY2020FY2021FY2022FY2023FY2024FY2025 RYTM: -, -, -, 0.63, 5.05, 0.78 RYTM TWST: 0.01, -, -, -, -, - TWST ZLAB: -, -, -, 0.00, 0.16, 0.29 ZLAB WGS: n/m, 0.03, 0.04, 0.25, 0.23, 0.18 WGS PRCT: n/m, 0.19, 0.26, 0.18, 0.13, 0.14 PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.05. A gap is a year with no number. A ring marks where a line starts: PRCT, RYTM, ZLAB, WGS have no earlier 10-K here.
CompanyFY2020FY2021FY2022FY2023FY2024FY2025
PRCT Dec n/m0.190.260.180.130.14
VCEL Dec ------
RYTM Dec ---0.635.050.78
TWST Sep 0.01-----
LMAT Dec ------
ZLAB Dec ---0.000.160.29
LGND Dec ------
WGS Dec n/m0.030.040.250.230.18
KRYS Dec ------
RVMD Dec ------
Peer median---0.250.230.29

EPS (diluted), FY2020 to FY2025

Diluted earnings per share, on today's share count after splits.

−$47036.00 $6.84 FY2020FY2021FY2022FY2023FY2024FY2025 VCEL: $0.06, −$0.16, −$0.35, −$0.07, $0.20, $0.32 VCEL RYTM: −$3.04, −$1.40, −$3.47, −$3.20, −$4.34, −$3.11 RYTM TWST: −$3.57, −$3.15, −$4.04, −$3.60, −$3.60, −$1.30 TWST LMAT: $1.04, $1.25, $0.93, $1.34, $1.93, $2.52 LMAT ZLAB: −$0.35, −$0.76, −$0.46, −$0.35, −$0.26, −$0.16 ZLAB LGND: −$0.18, $3.31, −$1.98, $2.94, −$0.22, $6.13 LGND WGS: −$47036.00, −$2.27, −$53.63, −$7.23, −$1.94, −$0.73 WGS KRYS: −$1.71, −$3.13, −$5.49, $0.39, $3.00, $6.84 KRYS RVMD: −$2.01, −$2.57, −$3.08, −$3.86, −$3.58, −$5.95 RVMD PRCT: −$14.47, −$3.63, −$1.96, −$2.24, −$1.75, −$1.72 PRCT
PRCT is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$47036.00 to $6.84. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out PRCT and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: PRCT's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.